Announcement & Notice - Disclosure - Investor Relations

Corporate Governance Stock Information Disclosure Financials Presentations and Events Analyst Coverage Notices-Replacement of Lost Share Certificates Subscribe to Updates

Home > Investor Relations > Disclosure

Disclosure

Listing Documents Financial Report/ESG information Announcement & Notice IR Journal

2021-07-20

APPOINTMENT OF CHIEF FINANCIAL OFFICER
2021-07-19

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON A COLLABORATION AGREEMENT WITH THE MOUNT SINAI HEALTH SYSTEM AND IN CONNECTION WITH NEUTRALIZING COVID-19 ANTIBODY
2021-07-16

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST DOSING OF LAST PATIENT WITH BATOCLIMAB (HBM9161) PHASE Ib/IIa TRIAL FOR TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER
2021-07-13

APPOINTMENT OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
2021-07-06

VOLUNTARY ANNOUNCEMENT - POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF BATOCLIMAB (HBM9161) IN GENERALIZED MYASTHENIA GRAVIS
2021-07-05

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021
2021-06-21

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 21 JUNE 2021
2021-06-17

VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT OF NEXT-GEN ANTI-CTLA-4 ANTIBODY HBM4003 IN COMBINATION WITH PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) ANTIBODY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER ("NSCLC")
2021-06-16

VOLUNTARY ANNOUNCEMENT - HARBOUR BIOMED AND DANA-FARBER CANCER INSTITUTE COLLABORATE TO ADVANCE NOVEL BIOTHERAPIES FOR CANCER TREATMENT
2021-06-09

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2021-06-09

REDESIGNATION OF DIRECTOR; APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES
2021-06-04

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
2021-06-02

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON THE ONGOING CLINICAL STUDIES FOR BATOCLIMAB (HBM9161)
2021-05-11

VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE Ib/IIa CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN AUSTRALIA
2021-05-06

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
2021-04-28

PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING
2021-04-28

NOTICE OF ANNUAL GENERAL MEETING
2021-04-28

PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING
2021-04-28

FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
2021-04-26

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

1 ···18 19 ···21